UNSPSC 51420000: Corticosteroids

This classification denotes manufactured adrenal cortex hormones (chemical substances having a specific regulatory effect on the activity of a certain organ or organs) or steroids that are similar to cortisol, the main glucocorticoid secreted by the adrenal cortex, or outer layer of the adrenal gland.

UNSPSC 51420000 Corticosteroids is a Family code that nominally covers steroid pharmaceuticals, but recent state and local solicitation activity under this code shows a mismatch with the code's abstract scope. The two most recent opportunities tagged to this code involve naloxone (an opioid antagonist used in overdose response) and direct-to-manufacturer pharmacy benefit program management — neither of which falls within corticosteroid procurement. Seminole County, Florida issued an IFB on June 30, 2026, to purchase 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, while the Texas Health and Human Services Commission posted an RFI on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription initiative outside traditional pharmacy benefit manager and group purchasing organization channels. The mismatch suggests either miscoding by the issuing bodies or that this code is being used as a catch-all for pharmaceutical procurement more broadly. State and local agencies using this code appear to span health departments, county community health systems, and state health and human services commissions.

Recent activity clusters in Florida and Texas. The Seminole County opportunity specifies quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with bids due July 26, 2023, and includes FEMA potential funding with associated federal compliance requirements. The Texas HHS RFI, a preliminary market-intelligence tool rather than a binding solicitation, sought responses by April 3, 2026, on vendor capacity for negotiated net pricing models and outcomes-based agreements. Neither opportunity specifies explicit set-asides or disadvantaged-enterprise restrictions. Given the limited recent activity and the apparent miscoding of opportunities to this code, pursuit should be informed by direct confirmation that corticosteroid procurement aligns with how issuing bodies are actually tagging their pharmaceutical needs.